26 May 2023
Research presented at the European Congress on Obesity has identified a link between semaglutide, a common weight-loss drug, and a notable reduction in cardiovascular risks in patients with obesity after one year of use. The study concludes the importance of weight-loss in these improvements.
Migraines and menopause symptoms linked to cardiovascular disease risk
19 Apr 2024
Risk of postpartum depression associated with stress during adolescence
19 Apr 2024
Surgery for hypoparathyroidism sees reduced facture rates
19 Apr 2024
Patients with type 2 diabetes taking antidepressants have a higher mortality risk
19 Apr 2024
Endocrine-disrupting chemical levels found at alarming levels in Australia
11 Apr 2024